Ara
Toplam kayıt 7, listelenen: 1-7
Turkish inappropriate medication use in the elderly (TIME) criteria to improve prescribing in older adults: TIME-to-STOP/TIME-to-START
(Springer, 2020)
Key summary pointsAim To meet the current need in different European countries for improving prescribing in older adults, we aimed to create an update screening tool getting origin from the two user friendly criterion sets: ...
Urinary tuberculosis: Still a challenge
(Springer, 2020)
Background Urinary tuberculosis (TB) is a challenging disease to cope with, as there has been no noticeable difference in basic diagnostic and therapeutic options in clinical practice over time. Purpose The aim of the ...
Urological infections in the developing world: An increasing problem in developed countries
(Springer, 2020)
Purpose Infectious diseases that often follow geographical distribution patterns are increasingly crossing such boundaries, aided by human travel and commerce. These pose a new challenge to physicians who are required to ...
Infections in urology: Slow progress reflected in clinical practice
(Springer, 2020)
This special topic issue on infections in urology features works from scientists, infectious disease specialists, and urologists. As seen in this work, there is still a noticeable heterogeneity in the global burden of the ...
Candida urinary tract infections in adults
(Springer, 2020)
Candiduria is commonly seen in hospitalized patients and most of the patients are asymptomatic, but it may be due to cystitis, pyelonephritis, prostatitis, epididymo-orchitis or disseminated candidiasis. Major risk factors ...
A single center cohort of 40 severe COVID-19 patients who were treated with convalescent plasma
(Tübitak Scientific & Technical Research Council Turkey, 2020)
Background/aim: A SARS-Cov2 infection which was first arised from Wuhan in December 2019 and named as COVID-19. Still there lacks either a specific treatment or a vaccine to treat COVID-19. Convalescent plasma (CP) was ...
Real-world efficacy and safety of Ledipasvir plus Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir +/- Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience
(AVES, 2020)
Background/Aims: This study aimed to evaluate the real-life efficacy and tolerability of direct-acting antiviral treatments for patients with chronic hepatitis C (CHC) with/without cirrhosis in the Turkish population.Material ...